Neuron23 Company
Neuron23 is a developer of drugs intended to treat Parkinson's disease and Alzheimer's disease.
Investors
Connections from
Founded Date:
2018-01-01
Total Funding:
213500000.0
Employee Number:
11-50
Funding Status:
Late Stage Venture
Technology:
['BioTech & HealthTech']
Last Funding Type:
Series C
Investors Number:
10.0
Last Funding Date:
2022-03-30
Industry:
Medical BioTech
Headquarters:
San Francisco, California, United States
Estimated Revenue:
$1M to $10M